Skyhawk Therapeutics
PrivateLast Round
Series B
Sep 14, 2021
Total Funding Raised
$141M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Skyhawk Therapeutics is a biotechnology company that develops small molecule drugs aimed at correcting ribonucleic acid expression through proprietary technology that targets specific binding sites during the splicing process to address diseases caused by exon skipping.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Skyhawk Therapeutics Comparables
Compare Skyhawk Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arrakis Therapeutics | 89% | |
| Expansion Therapeutics | 83% | |
| Remix Therapeutics | 81% |
Skyhawk Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 14, 2021 | ||||
| VC Round | Jun 26, 2018 | ||||
| Seed | Jan 23, 2018 |
Skyhawk Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GreatPoint Ventures | Series B, VC Round |
| Agent Capital | VC Round |
| Good Growth Capital | Seed |
| Bramalea Partners | Series B |
| Acks | Seed |
| GreatPoint Ventures | VC Round |
| Fidelity Management & Research Company | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 62% MoM.
- Jul 5, 2026
SKY-0515 disclosed as Huntington's disease asset in development.
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
Skyhawk Therapeutics, Inc.'s RNA-splicing candidate for Huntington's disease improves patients' symptoms in an extension to a Phase 1/2 trial as it moves to pivotal development.
Skyhawk Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Skyhawk Therapeutics's valuation, stock price, and market status.
Is Skyhawk Therapeutics a public or private company?
Skyhawk Therapeutics is a private company.
What is the current stock price of Skyhawk Therapeutics?
Skyhawk Therapeutics is a private company, so its shares have no public market price. Caplight tracks Skyhawk Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Skyhawk Therapeutics worth (valuation)?
Valuation information for Skyhawk Therapeutics is not publicly available.
Can I buy Skyhawk Therapeutics stock?
Skyhawk Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Skyhawk Therapeutics's last funding round?
Skyhawk Therapeutics's most recent funding round was Series B on September 14, 2021.
Who are the main investors in Skyhawk Therapeutics?
Key investors in Skyhawk Therapeutics include GreatPoint Ventures, Good Growth Capital, Acks, Fidelity Management & Research Company.
Will Skyhawk Therapeutics IPO soon?
No public IPO plans have been announced for Skyhawk Therapeutics.
How can I track Skyhawk Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Skyhawk Therapeutics's shares on secondary markets.